(Q36812875)

16 August 2017

1 reference

title

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs (English)

1 reference

16 August 2017

1 reference

Gopi Shankar

1

1 reference

16 August 2017

Charles Pendley

series ordinal

2

1 reference

16 August 2017

Kathryn E Stein

series ordinal

3

1 reference

16 August 2017

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

25

1 reference

16 August 2017

5

1 reference

16 August 2017

555-561

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt1303

16 August 2017

0 references

cites work

Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects

1 reference

7 January 2021

Immunogenicity of therapeutic proteins: clinical implications and future prospects

1 reference

7 January 2021

Spontaneous inhibitors to coagulation factors

1 reference

7 January 2021

Scientific and regulatory considerations on the immunogenicity of biologics

1 reference

7 January 2021

Immunogenicity of therapeutic proteins

1 reference

7 January 2021

Immunogenicity of xenopeptide hormone therapies

1 reference

7 January 2021

Thrombocytopenia caused by the development of antibodies to thrombopoietin

1 reference

7 January 2021

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

7 January 2021

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

7 January 2021

Facilitation of the growth promoting effect of growth hormone (GH) by an antibody to methionyl-GH

1 reference

7 January 2021

Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression

1 reference

7 January 2021

OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3

1 reference

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

7 January 2021

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy

1 reference

7 January 2021

Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)

1 reference

7 January 2021

Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.

1 reference

7 January 2021

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

7 January 2021

Factors influencing the immunogenicity of therapeutic proteins

1 reference

7 January 2021

Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures

1 reference

7 January 2021

Clinical impact of antibody formation to botulinum toxin A in children

1 reference

7 January 2021

Identifiers

DOI

10.1038/NBT1303

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference